Loss of Functionally Redundant p38 Isoforms in T Cells Enhances Regulatory T Cell Induction*

Received for publication, October 24, 2016, and in revised form, December 1, 2016. Published, JBC Papers in Press, December 23, 2016, DOI 10.1074/jbc.M116.764548

Morisada Hayakawa†‡, Hiroko Hayakawa†‡, Tsvetana Petrova‡§, Patcharee Ritprajak†‖, Ruhcha V. Sutavani‡, Guillermina Yanek Jiménez-Andrade§, Yasuyo Sano‡, Min-Kyung Choo‡, John Seavitt‡, Ram K. C. Venigalla**; Kinya Otsu†; Katia Georgopoulos‡‡; and Jin Mo Park‡

From the †Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, the ‡Division of Cell Signalling and Immunology, School of Life Sciences, Wellcome Trust Building, and the §Division of Cell Biology, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan, the ‖Department of Cell and Molecular Biology, Chulalongkorn University, Bangkok 10330, Thailand, and the ¶Cardiovascular Division, King’s College London, London SE5 9NU, United Kingdom

Edited by Luke O’Neill

The evolutionarily conserved protein kinase p38 mediates innate resistance to environmental stress and microbial infection. Four p38 isoforms exist in mammals and may have been co-opted for new roles in adaptive immunity. Murine T cells deficient in p38α, the ubiquitously expressed p38 isoform, showed no readily apparent cell-autonomous defects while expressing elevated amounts of another isoform, p38β. Mice with T cells simultaneously lacking p38α and p38β displayed lymphoid atrophy and elevated Foxp3+ regulatory T cell frequencies. Double deficiency of p38α and p38β in naive CD4+ T cells resulted in an attenuation of MAPK-activated protein kinase (MK)-dependent mTOR signaling after T cell receptor engagement, and enhanced their differentiation into regulatory T cells under appropriate inducing conditions. Pharmacological inhibition of the p38-MK-mTOR signaling module produced similar effects, revealing potential for therapeutic applications.

The T cell receptor (TCR)3 and receptors for costimulatory molecules and cytokines deliver key signals for the development and function of T cells. Upon ligand binding, these receptors trigger intracellular signaling cascades that are integrated to elicit changes in gene expression and cellular phenotype. In peripheral naive T cells, for example, antigen encounter and costimulation in conjunction with exposure to specific cytokines lead to the induction of a gene transcription program that specifies differentiation into a functionally distinct subset of effector, memory, or regulatory cells. The magnitude as well as the nature of receptor-initiated signals contributes to determining the fate and functional capabilities of activated T cells. Modulating intracellular signaling in T cells by pharmacological means can dampen, augment, or re-route immune responses, an approach that may be harnessed to suppress immune-mediated disorders and enhance antitumor immunity.

Homologues of p38, a MAPK family member, are found in organisms ranging from yeast to humans. In single-celled life, p38 is activated upon stress and damage, and signals to evoke cell-autonomous mechanisms for adaptation, repair, and survival (1, 2). The role of p38 signaling in multicellular organisms extends to antimicrobial defense, with p38-dependent phosphorylation events at work downstream of receptors for immune signals (3–5). In most physiological contexts, p38 activation in mammalian cells occurs through a “classical” MAPK cascade, in which p38 is phosphorylated by the MAPK kinases MKK3 and MKK6, which themselves are activated by stimulus-specific MAPK kinase kinase-mediated phosphorylation (6).

Four mammalian p38 isoforms (p38α, p38β, p38γ, and p38δ) have evolved to assume specialized but partly redundant physiological roles. Of particular importance to immune function is p38α, the isoform most widely expressed in tissues (7, 8) and involved in cell responses to cytokines and microbial products (9–11). Moreover, p38α was originally identified as the molecular target of a class of small-molecule anti-inflammatory compounds (12), and since this initial finding p38α has been implicated in signaling processes associated with a host of diseases of inflammatory etiology (6). Cell type-specific loss of p38α signaling in mice, with p38α gene ablation restricted to epithelial cells, myeloid cells, or dendritic cells, was found to prevent or ameliorate inflammatory responses and pathology in ultraviolet radiation-induced dermatitis (13, 14), chemically induced colitis (15), contact hypersensitivity reactions (16), and experimental autoimmune encephalomyelitis (17).

The activation of p38 in T cells occurs not only through the classical MKK3/6-mediated process (18–20) but also via an
alternative pathway involving p38 phosphorylation by the TCR-proximal tyrosine kinase ZAP70 (21). ZAP70-activated p38α and p38β serve some redundant functions in T cells (22), and their activating phosphorylation sites and substrate specificities differ from those of MKK3/6-activated counterparts (23). Several studies examined the in vivo effects of impaired p38 function in T cells by using pharmacological p38 inhibitors (24, 25), dominant-negative p38α and MKK transgenes (19, 24–27), p38α- and MKK-null alleles (18, 28–30), and p38 gene knock-in alleles selectively precluding alternative activation (22, 31, 32). The findings from these approaches suggested a role for T cell p38 signaling in thymocyte development, TCR-induced proliferation and apoptosis, IFN-γ, IL-2, and IL-17A production, and autoimmune diseases such as collagen-induced arthritis and experimental autoimmune encephalomyelitis. Other studies that examined mice with T cells lacking p38α alone or both p38α and p38β, however, did not observe substantial effects on IFN-γ and IL-17A production or experimental autoimmune encephalomyelitis (17). The role of p38 signaling in T cells, therefore, remains debatable, its potential as a target for anti-inflammatory therapy yet to be definitely appraised.

In this study, we find as-yet-unreported effects of ablating p38α and p38β in T cells: mice with T cells simultaneously deficient in the two p38 isoforms exhibit enhanced regulatory T (Treg) cell induction and attenuated allergic inflammation when challenged with epicutaneous antigen. In vitro differentiation experiments confirm the role of p38 signaling in limiting Treg cell induction, and identify how p38α and p38β cooperate to perform this role. Our findings suggest inhibition of p38 signaling as a novel means to promote Treg cell generation and treat immune-mediated diseases.

Results

Development and Maintenance of T Cells Lacking p38α and p38β—We previously reported that mice with T cell-specific ablation of p38α (Mapk14β/−-LckCre; Δα) showed moderate lymphoid atrophy, and had decreased proportions of CD8+ subsets among lymph node and splenic T cells (16). Combined, these changes translated to a decline in the absolute number of CD8+ T cells available for antigen-specific immune responses such as contact hypersensitivity reactions. Nevertheless, T cells from these mice, taken individually, remained functionally competent throughout the immune response: in hapten-exposed animals, p38α-deficient T cells were efficiently primed to become cytokine-producing effector cells, and formed a memory population that could transfer hapten sensitivity to naïve mice (16). This may be due either to a lack of critical cell-autonomous functions of p38α in T cells during immune responses or to functional compensation by other p38 isoforms. Such functional redundancy has been documented for p38α and p38β in various cell types including T cells (22, 33). Of note, p38β expression in mice was prominent in T cells compared with other cell types (Fig. 1A), and further elevated in lymph node and splenic T cells with p38α ablation (Fig. 1B).

To examine whether p38α and p38β exert redundant functions in T cells, we crossed Δα mice with p38β-null mice (Mapk11β/−; Δβ) to generate mice with T cells lacking both p38α and p38β (Mapk14β/−-LckCre-Mapk11β/−; ΔαΔβ). T cells from ΔαΔβ mice did not express detectable amounts of both p38 isoforms (Fig. 1C). The size and cellularity of the thymus, lymph nodes, and spleen of ΔαΔβ mice decreased compared with those of wild-type (WT) mice (Fig. 1, D and E). The lymphoid tissues of Δα and Δβ mice tended to be atrophic too, but to lesser extents than ΔαΔβ counterparts. Single and double deficiency of p38α and p38β in T cells did not prevent the thymic development of CD4+ and CD8+ T cells or their homing to and maintenance in the lymph nodes and spleen (Fig. 1F). In keeping with our previous report (16), the proportions of lymph node and splenic CD8+ T cells were lower in Δα mice than in WT mice, but not further reduced by the additional loss of p38β in ΔαΔβ mice (Fig. 1F).

Signaling by p38α and p38β in T Cells—We examined the effects of p38 deficiency on TCR-induced intracellular signaling in naïve CD4+ T cells. Compared with T cells lacking only either isoform, T cells from ΔαΔβ mice exhibited a more complete abrogation of p38 phosphorylation after treatment with TCR agonists, anti-CD3 and anti-CD28 antibodies (Fig. 2, A and B). Loss of p38 has been shown to potentiate signaling by other MAPK family members, ERK and JNK, in a multitude of cell types (34). Correspondingly, ΔαΔβ T cells showed increased phosphorylation, and thus activation, of ERK and JNK upon TCR stimulation (Fig. 2A). We observed that MAPK-activated protein kinase (MK) 2, a protein kinase immediately downstream of p38, was constitutively phosphorylated in cultured T cells independently of TCR stimulation. Nevertheless, MK2 phosphorylation was abolished in ΔαΔβ T cells, but not Δα and Δβ T cells (Fig. 2, A and B), suggesting that p38 was indispensable for steady-state phosphorylation of MK2.

Some previous studies suggested a connection between the p38-MK2 signaling module and the mechanistic target of rapamycin (mTOR): p38 was required for stress-induced mTOR signaling in arsenite-exposed fibroblasts, hypoxic-reoxygenated cardiomyocytes, and anisomycin-treated macrophages (35–37). Anisomycin-induced mTOR activation has been attributed to the ability of MK2 to phosphorylate and inactivate the mTOR inhibitor TSC2 (37, 38). It remained unexplored, however, whether signaling events consistent with this model occurred in T cells during TCR activation. We found that the loss of MK2 activation in ΔαΔβ T cells was accompanied by a marked reduction in the phosphorylation of TSC2 at serine-1254, which is associated with MK2-dependent inactivation (Fig. 2A). In parallel, mTOR pathway activation, as indicated by S6K and S6 phosphorylation, was greatly weakened in ΔαΔβ T cells but persisted in Δα and Δβ T cells, albeit in lower magnitudes than in WT counterparts (Fig. 2, A and B). TCR-induced S6 phosphorylation was also diminished in CD4+ T cells lacking MK2 and the related protein kinase MK3 (Fig. 3, A–F), which served overlapping signaling functions (39, 40). Intriguingly, TCR-induced S6 phosphorylation remained intact in CD8+ T cells lacking MK2 and MK3 (Fig. 3, F and G). In summary, p38-dependent activation and regulation of intracellular signaling events in naïve CD4+ T cells were abolished by ablation of both p38α and p38β but not either alone.
Activation and Th Effector Differentiation of T Cells Lacking p38\textsubscript{\textalpha}/p38\textsubscript{\textbeta}—We sought to identify functional defects in T cells that resulted from loss of p38 signaling. First, we isolated total (CD3\textsuperscript{+}) splenic T cells from WT and \(\alpha\beta\Delta\) mice and stimulated them with anti-CD3 and anti-CD28 antibodies. The proliferation rate of TCR-stimulated CD4\textsuperscript{+} T cells was substantially reduced by p38\textsubscript{\textalpha} and p38\textsubscript{\textbeta} deficiency (Fig. 4A). These effects could indicate a cell-autonomous role for p38 signaling in TCR-induced proliferation or, alternatively, a contribution of a non-cell-autonomous mechanism that suppressed T cell activation more effectively without the p38 isoforms. Treg cells, contained in the total splenic T cell preparations, might exert the suppressive effect under the latter scenario.

To exclude or minimize the possible influence of Treg cells, we performed subsequent experiments using cell preparations devoid of antigen-experienced T cells including Foxp3\textsuperscript{+} cells. To this end, the CD4\textsuperscript{+} CD62L\textsuperscript{−} subset was purified from splenic T cells and subjected to TCR stimulation. Naïve T cells thus prepared from WT and \(\Delta\alpha\Delta\beta\) mice proliferated at only moderately reduced rates (Fig. 4B) compared with the effects seen with total splenic T cells. Naïve CD4\textsuperscript{+} T cells from WT and \(\Delta\alpha\Delta\beta\) mice produced comparable amounts of IFN-\(\gamma\), IL-13, and IL-17A upon TCR stimulation (Fig. 4C), and differentiated into...
from Δαβ mice (Fig. 5C), suggesting that p38 signaling served to limit Foxp3 expression even before the Treg phenotype was established. The suppressive function of Treg cells from Δαβ mice, as determined by the ability to inhibit TCR-induced proliferation of naïve CD4⁺ T cells, was intact, and in fact slightly enhanced compared with that of WT Treg cells (Fig. 5E).

We next investigated Treg cell formation in vivo. Notably, Δαβ mice in a steady-state condition exhibited a small but consistent increase in Treg cell frequency: CD4⁺ T cells from the thymus and spleen of Δαβ mice contained elevated Foxp3⁺ fractions (Fig. 5F and G). To examine Treg cell induction during T cell-mediated immune responses, we subjected WT and Δαβ mice to an experimental condition that elicited contact hypersensitivity reactions. In this model of allergic dermatitis, epicutaneous exposure to a small-molecule antigen or hapten establishes T cell immunity and, upon re-encounter with the hapten, induces T cell-mediated inflammation accompanied by skin rashes and swelling. Δαβ mice displayed greatly attenuated responses to the hapten 2,4-dinitrofluorobenzene (DNFB; Fig. 5H) and, simultaneously, a massive expansion of the Treg cell compartment in the skin-draining lymph node (Fig. 5I and J).

Given the observations described above, p38 signaling was not essential for T cell development and steady-state maintenance. Nevertheless, p38 deficiency in T cells produced perceptible effects in Δαβ mice—altered sizes of CD8⁺ and CD4⁺Foxp3⁺ T cell subpopulations. It was conceivable that these effects resulted from impaired p38 signaling in cell types other than T cells, as Δαβ mice had systemic p38β deficiency. To address this possibility, we examined the lymphoid tissues of RAG1-deficient mice that were sublethally irradiated and engrafted with bone marrow from Δαβ mice. These radiation chimeras, in which deficiency of not only p38α but also p38β was restricted to lymphocytes, exhibited decreased CD8⁺ and increased CD4⁺Foxp3⁺ T cell subsets compared with control chimeras engrafted with WT bone marrow (Fig. 6A and B). Hence, the changes in the frequency of T cell subsets in Δαβ mice were likely attributable to the loss of cell-autonomous p38 function. The influence of Cre recombinase-mediated toxicity, if any, was also ruled out based on the normal ranges of CD8⁺ and CD4⁺Foxp3⁺ T cell abundance in LckCre mice (Fig. 6C and D).

Role of p38α/β-MK2/3-mTOR Signaling in T Cell Induction—Our analysis of Δαβ mice revealed novel effects of loss of p38 signaling in CD4⁺ T cells: increased Foxp3 expression and enhanced induction of fully functional Treg cells. We sought to identify the molecular mechanism whereby p38 signaling modulated Treg cell induction, and explored the possible involvement of the protein kinases whose activation was regulated by or dependent on p38. Excessive activation of ERK and JNK, seen in TCR-stimulated Δαβ T cells (Fig. 2A and B), might contribute to enhancing Treg cell induction; we refuted this possibility, however, as pharmacological inhibition of their activation did not significantly reduce the efficiency of Treg cell induction from Δαβ T cells (Fig. 7A).

Further, deficiency of mitogen- and stress-activated kinase (MSK) 1 and MSK2, which are phosphorylated by and relay...
signals from ERK and p38 (6), did not profoundly affect Treg cell induction (Fig. 7B).

As shown above, S6 protein phosphorylation, an event downstream of mTOR activation, was induced in WT CD4+ T cells upon TCR stimulation but substantially diminished in Δαβ and MK2/3-double knock-out (DKO) counterparts (Fig. 2, A and B; and Fig. 3, A–E). We therefore explored MK2/3 and mTOR as possible links for p38-dependent modulation of Treg cell induction. Indeed, pharmacological inhibition and genetic ablation of mTOR have been shown to enhance Foxp3 expression in CD4+ T cells, and promote their differentiation into Treg cells (41, 42), paralleling the effect of loss of p38 signaling. To verify the role of p38α/β-MK2/3-mTOR signaling in regulating Treg cell induction, we tested small-molecule compounds acting on distinct points of this protein kinase cascade: SC409, PF3644022, and rapamycin. These compounds, inhibiting p38, MK2, and mTOR, respectively, suppressed TCR-induced S6 phosphorylation as did genetic ablation of p38 (Fig. 7C and D). Further, these compounds augmented in vitro Treg cell induction to similar extents (Fig. 7E).

To obtain genetic evidence for MK2/3-dependent regulation of Treg cell induction, we investigated T cells isolated from MK2/3-DKO mice. Double deficiency of MK2 and MK3 in mice did not perturb the development and maintenance of CD4+ and CD8+ T cells (Fig. 8A). We compared the relative fitness of WT and MK2/3-DKO T cells in Treg cell formation in vitro by mixing equal numbers of naïve CD4+ T cells from WT CD45.1+ mice and MK2/3-DKO CD45.2+ mice and subjecting them to a Treg-skewing condition. The contribution of CD45.2+ cells to the Treg cell pools obtained at day 5 was greater than that of CD45.1+ cells (Fig. 8B and C). The efficiency of naïve-to-Treg conversion was also significantly higher with MK2/3-DKO T cells (Fig. 8D).
ilar to Δαβ mice, MK2/3-DKO mice exhibited a subtle but significant increase in steady-state Treg cell frequency in the spleen (Fig. 8, E and F). In summary, our findings point to the p38/MK2/3-mTOR cascade as a new actionable target for promoting the induction of immunosuppressive Treg cells.

Discussion

A role for the p38 signaling pathway in immune responses was suspected early on, and the promise of effectively treating immune-mediated diseases by suppressing this pathway has been driving efforts to understand how this pathway contributes to immunity and inflammation. The findings of this study suggest a role for p38 signaling in several aspects of T cell biology: mice with T cell-restricted ablation of p38α and p38β expression exhibited reduced numbers of T cells and increased frequencies of Treg cells in lymphoid tissues. The decreases in contact hypersensitivity reactions in these mice were likely attributable to either or both of these two effects. From an extensive investigation of protein kinases activated downstream of the TCR, we identified the p38α/β-MK2/3-mTOR cascade as a key signaling module regulating Treg cell induction while ruling out the involvement of ERK, JNK, and MSK. Pharmacological agents interfering with this multilayered protein kinase module may improve the efficiency of generating or expanding Treg cells ex vivo for adoptive cell transfer therapy.

TCR and cytokine receptors play key roles in Treg cell development and function, transmitting intracellular signals that are integrated to induce Foxp3 expression in naive CD4+ T cells and stabilize it in Treg-committed cells. Cytokines provide major cues for the skewing of CD4+ T cell differentiation, but the strength of TCR signaling also contributes to determining the fate of activated T cells and, in particular, the efficiency of Treg cell formation (43, 44). Signaling by p38 may be pivotal to interpreting the intensity of TCR activation and tuning Treg signature expression accordingly. We have demonstrated that the loss of p38 signaling in T cells is associated with enhanced Treg cell induction. This effect is in accord with the requirement for p38 in TCR-induced mTOR activation. While we note
MK/2/3-mediated phosphorylation of TSC2 as a potential mechanistic link between p38 and mTOR, it is also possible that MK2/3 may act on a signaling event upstream of TSC2 as the two MKs have been found to affect Toll-like receptor-induced production of phosphatidylinositol 3,4,5-trisphosphate, a phospholipid activator of AKT-mTOR signaling (45). Of note, there were earlier reports of Treg cell induction enhanced by genetic ablation of other protein kinases downstream of TCR, as seen with T cells lacking the TEC family kinase ITK or doubly deficient for the MAPK kinase kinases MEKK2 and MEKK3 (20, 46). Intriguingly, TCR-induced p38 and mTOR activation was impaired in these T cells (20, 46, 47). It remains to be seen whether the p38-MK2/3-mTOR module serves as a nodal point of intracellular signaling in T cells where upstream inputs are integrated into a scalable signal for Foxp3-driven Treg cell induction.

Experimental Procedures

Animals—Δα (Mapk14fl/fl-LckCre), Δβ (Mapk11−/−), and MAPK-activated protein kinase (MK) 2/3-double knock-out (DKO) mice were previously described (16, 40, 48). Δαβ...
(Mapk14LckCre-Mapk11−/−) mice were generated by crossing Δα and Δβ mice. All mice were on a C57BL/6 background. Contact hypersensitivity to DNFB was induced as described (16). For bone marrow engraftment, 8-week-old Rag1−/− mice (The Jackson Laboratory) were sublethally irradiated (450 rads), engrafted with bone marrow cells (4 × 10^6) from WT and Δαβ mice, and maintained on sulfamethoxazole- and trimethoprim-supplemented drinking water for 8 weeks prior to analysis. All animal experiments were conducted under IACUC-approved protocols.

Reagents—DNFB, brefeldin A, and PF3644022 were from Sigma-Aldrich; SC409, PD98059, SP600125, and rapamycin from EMD Millipore; CFSE from Life Technologies; IFN-γ, IL-2, IL-4, IL-6, and TGF-β from Peprotech. Fluorescent-conjugated antibodies against the following markers were used in flow cytometry: CD3 (145–2C11), CD4 (GK1.5 and RM4–5), CD8 (53–6.7), CD25 (PC61.5), Foxp3 (anti-mouse/rat staining kit), IFN-γ (XMG1.2), IL-4 (BVD6–24G2), IL-17A (eBio17B7; all from eBioscience). Antibodies against the following proteins were used in cell stimulation, Fc receptor blocking, and cytokine neutralization: CD3 (145–2C11), CD28 (37.51), IFN-γ (XMG1.2), IL-12 (C17.8), IL-4 (11B11), CD16/CD32 (2.4G2; all from BD Pharmingen); and hamster IgG (MP Biomedicals). Antibodies against the following proteins were used in immunoblotting: ERK (9102), phosphorylated (p-) p38 (9211), p-JNK (9251), p-ERK (9101), p-S6K1 (9205), p-S6 (4858), p-MK2 (3007), p-TSC2 (3616; all from BD Pharmingen); and actin (A4700; Sigma-Aldrich).

T Cell Isolation and Flow Cytometry—CD3+ T cells and naïve CD4+ T cells were isolated from the thymus, lymph nodes, and spleen of 6–8-week-old mice using the Pan T cell Isolation Kit and the CD4+ CD62L+ T Cell Isolation Kit, respectively (Miltenyi Biotec). Single-cell suspensions obtained from mice were...
incubated with Fc receptor-blocking anti-CD16/CD32, stained with fluorescent-conjugated antibodies, and analyzed by flow cytometry using FACSCanto and LSRFortessa (BD Biosciences) and FlowJo software (Tree Star).

**T Cell Activation in Vitro**—Naïve CD4⁺ T cells from the spleen were stimulated with plate-bound anti-CD3 (10 µg/ml) and soluble anti-CD28 (2 µg/ml). Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled T cells were stimulated with anti-CD3 and anti-CD28 for 3 days, and analyzed by flow cytometry. To analyze Treg suppressive function, lymph node and splenic CD4⁺CD25⁺ cells were isolated using the Regulatory T Cell Isolation Kit (Miltenyi Biotec). CFSE-labeled naïve CD4⁺ T cells were mixed with CD4⁺CD25⁺ cells, stimulated with anti-CD3 and anti-CD28 for 3 days, and analyzed for proliferation.

**T Cell Differentiation in Vitro**—To induce T cell differentiation into Th effector cells, naïve CD4⁺ T cells from the spleen were incubated with the following agents: Th1, IL-2 (20 ng/ml), IL-12 (10 ng/ml), IFN-γ (10 ng/ml), anti-IL-4 (10 µg/ml); Th2, IL-2 (20 ng/ml), IL-4 (10 ng/ml), anti-IFN-γ (10 µg/ml), and anti-IL-12 (10 µg/ml); and Th17, IL-6 (20 ng/ml), TGF-β (2.5 ng/ml), anti-IFN-γ (2 µg/ml), anti-IL-4 (2 µg/ml), soluble anti-CD28 (1 µg/ml), soluble anti-CD3 (0.25 µg/ml), and plate-bound anti-hamster IgG (0.12 µg/ml). After 5 days of differentiation, cells were treated with phorbol myristate acetate (50 ng/ml) and ionomycin (1 µM) in the presence of brefeldin A (10 µg/ml) for 5 h and analyzed by flow cytometry. For Treg cell induction, naïve CD4⁺ T cells were stimulated with anti-CD3 and soluble anti-CD28 (2 µg/ml) for 5 days as in Fig. 5C. The percentage of naïve CD4⁺ T cells from the indicated mouse tissues was determined by flow cytometry. Cell percentages are shown as mean ± S.D. (n = 7, each group; *p < 0.05, **p < 0.001).

**FIGURE 7.** The p38α/β-MK2/3-mTOR signaling module regulates Treg cell induction. A and B, naïve CD4⁺ T cells from the indicated mice were cultured in a Treg-skewing condition for 5 days as in Fig. 5A. The cells were treated with vehicle (DMSO), PD98059 (PD), or SP600125 (SP) throughout the culture period (A) or without any of these compounds (B). CD25 and Foxp3 expression was analyzed by flow cytometry. C and D, naïve CD4⁺ T cells from the indicated mice were left unstimulated or stimulated with anti-CD3 and anti-CD28. The cells were left untreated (C) or treated with vehicle (DMSO), the p38 inhibitor SC409 (SC), the MK2 inhibitor PF3644022 (PF), and rapamycin (Rm) 1 h before stimulation (D). Whole cell lysates were prepared after the indicated durations of stimulation and analyzed by immunoblotting. p-, phosphorylated, E, naïve CD4⁺ T cells were cultured in a Treg-skewing condition for 5 days as in Fig. 5A in the presence of the indicated agents throughout the culture period. CD25 and Foxp3 expression was analyzed by flow cytometry. Data are representative of two (A and E) or three experiments (B–D) with similar results.
and anti-CD28 in the presence of IL-2 (20 ng/ml), TGF-β (5 ng/ml), anti-IFN-γ (10 μg/ml), and anti-IL-4 (10 μg/ml) for 5 days. Cells were treated with SC409 (10 M) where indicated.

Protein and RNA Analysis—Whole cell lysates were prepared and analyzed by immunoblotting as described (49). Immunoblot signals were quantified by using ImageJ software (National Institutes of Health). Cytokine concentrations in culture supernatants were measured by ELISA. Real-time quantitative PCR was performed using gene-specific primers.

Statistical Analysis—Data values are expressed as mean ± S.E. or mean ± S.D. p values were obtained with the unpaired, two-tailed Student’s t test unless otherwise indicated.

Author Contributions—M. H., K. O., K. G., J. S. C. A., and J. M. P. designed the study and wrote the report. M. H., H. H., T. P., P. R., R. V. S., G. Y. J.-A., Y. S., M.-K. C., J. S., K. R. C. V., and J. M. P. generated and analyzed p38 and MK KO mice. M. H., T. P., P. R., R. V. S., R. K. C. V., and J. M. P. performed in vitro experiments. M. H., P. R., K. O., K. G., J. S. C. A., and J. M. P. interpreted data. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgments—We thank Matthias Gaestel and Natalia Ronkina for MK2/3-DKO mice, and we thank the Core Center of Research Apparatus (Jichi Medical University) for the management of LSRFortessa. The management of LSRFortessa at the Core Center of Research Apparatus (Jichi Medical University) was subsidized by Keirin Race funds from the JKA Foundation.

References
1. Brewster, J. L., de Valoir, T., Dwyer, N. D., Winter, E., and Gustin, M. C. (1992) An osmosensing signal transduction pathway in yeast. Science 259, 1760–1763
2. Degols, G., Shiozaki, K., and Russell, P. (1996) Activation and regulation of the Spc1 stress-activated protein kinase in Schizosaccharomyces pombe. Mol. Cell Biol. 16, 2870–2877
3. Han, S. I., Choi, K. Y., Brey, P. T., and Lee, W. J. (1998) Molecular cloning and characterization of a Drosophila p38 mitogen-activated protein kinase. J. Biol. Chem. 273, 569–374
4. Han, Z. S., Enslen, H., Hu, X., Meng, X., Wu, I. H., Barrett, T., Davis, R. J., and Ip, Y. T. (1998) A conserved p38 mitogen-activated protein kinase pathway regulates Drosophila immunity gene expression. Mol. Cell Biol. 18, 3527–3539
5. Kim, D. H., Feinbaum, R., Altoing, G., Emerson, F. E., Garsin, D. A., Inoue, H., Tanaka-Hino, M., Hisamoto, N., Matsumoto, K., Tan, M. W., and Ausubel, F. M. (2002) A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297, 623–626
6. Arthur, J. S., and Ley, S. C. (2013) Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13, 679–692
7. Jiang, Y., Gram, H., Zhao, M., New, L., Gu, J., Feng, L., Di Padova, F., Ulevitch, R. J., and Han, J. (1997) Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38α. J. Biol. Chem. 272, 30122–30128
8. Hale, K. K., Trollinger, D., Rihanek, M., and Mantehy, C. L. (1999) Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J. Immunol. 162, 4246–4252
9. Freshney, N. W., Rawlinson, L., Guesdon, F., Jones, E., Cowley, S., Huan, J., and Sakkalvara, J. (1994) Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039–1049
10. Han, J. L., Lee, J. D., Bibbs, L., and Ulevitch, R. J. (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808–811
11. Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazaes, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027–1037
12. Lee, J. C., Laydon, I. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Stricker, J. E., McLaughlin, M. M., Siemans, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746
13. Kim, C., Sano, Y., Todorovka, K., Carlson, B. A., Arpa, L., Celada, A., Lawrence, T., Otsu, K., Brissette, J. L., Arthur, J. S., and Park, J. M. (2008) The kinase p38α serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat. Immunol. 9, 1019–1027
14. Sano, Y., and Park, J. M. (2014) Loss of epidermal p38α signaling prevents UVR-induced inflammation via acute and chronic mechanisms. J. Invest. Dermatol. 134, 2231–2240
15. Otsuka, M., Kang, Y. J., Ren, J., Jiang, H., Wang, Y., Omatu, M., and Han, I. (2010) Distinct effects of p38α deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 138, 1255–1265
16. Ritprajak, P., Hayakawa, M., Sano, Y., Otsu, K., and Park, J. M. (2012) Cell type-specific targeting dissociates the therapeutic from the adverse effects of protein kinase inhibition in allergic skin disease. Proc. Natl. Acad. Sci. U.S.A. 109, 9089–9094
17. Huang, G., Wang, Y., Vogel, P., Kangennati, T. D., Otsu, K., and Chi, H. (2012) Signaling via the kinase p38α programs dendritic cells to drive TH17 differentiation and autoimmunity inflammation. Nat. Immunol. 13, 152–161
18. Tanaka, N., Kamanaka, M., Enslen, H., Dong, C., Wysk, M., Davis, R. J., and Flavell, R. A. (2002) Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep. 3, 785–791
19. Hsu, S. C., Wu, C. C., Han, J., and Lai, M. Z. (2003) Involvement of p38 mitogen-activated protein kinase in different stages of thymocyte development. Blood 101, 970–976
20. Chang, X., Liu, F., Wang, X., Lin, A., Zhao, H., and Su, B. (2011) The kinases MEK2 and MEK3 regulate transforming growth factor-β-mediated helper T cell differentiation. Immunity 34, 201–212
21. Salvador, J. M., Mittelstadt, P. R., Guszczynski, T., Copeland, T. D., Yamaguchi, H., Appella, E., Fornace, A. J., Jr, and Ashwell, J. D. (2005) Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat. Immunol. 6, 390–395
22. Irmanova, L., Giardino Torchia, M. L., Sarma, N. D., Mittelstadt, P. R., and Ashwell, J. D. (2011) Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation. Blood 118, 3280–3289
23. Mittelstadt, P. R., Yamaguchi, H., Appella, E., and Ashwell, J. D. (2009) T cell receptor-mediated activation of p38α by mono-phosphorylation of the activation loop results in altered substrate specificity. J. Biol. Chem. 284, 15469–15474
24. Rincón, M., Enslen, H., Raingeaud, J., Recht, M., Zapol, T., Su, M. S., Pennix, L. A., Davis, R. J., and Flavell, R. A. (1998) Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 17, 2817–2829
25. Noubrade, R., Krementsov, D. N., Del Rio, R., Thornton, T., Nagaleekar, V., Saligrama, N., Spitzack, A., Spach, K., Sabio, G., Davis, R. J., Rincon, M., and Teuscher, C. (2011) Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118, 3290–3300
26. Diehl, N. L., Enslen, H., Fortner, K. A., Merritt, C., Stetson, N., Charland, C., Flavell, R. A., Davis, R. J., and Rincon, M. (2000) Activation of the p38 mitogen-activated protein kinase pathway arrests cell cycle progression and differentiation of immature thymocytes in vivo. J. Exp. Med. 191, 321–334
27. Merritt, C., Enslen, H., Diehl, N., Conze, D., Davis, R. J., and Rincon, M. (2000) Activation of p38 mitogen-activated protein kinase in vivo selec-



tively induces apoptosis of CD8⁺ but not CD4⁺ T cells. Mol. Cell Biol. 20, 936–946

28. Lu, H. T., Yang, D. D., Wysk, M., Gatti, E., Mellman, I., Davis, R. J., and Flavell, R. A. (1999) Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J. 18, 1845–1857

29. Kim, J. M., White, J. M., Shaw, A. S., and Sleckman, B. P. (2005) MAPK p38α is dispensable for lymphocyte development and proliferation. J. Immunol. 174, 1239–1244

30. Berenson, L. S., Yang, J., Sleckman, B. P., Murphy, T. L., and Murphy, K. M. (2006) Selective requirement of p38 MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses. J. Immunol. 176, 4616–4621

31. Jirmanova, L., Sarma, D. N., Jankovic, D., Mittelstadt, P. R., and Ashwell, J. D. (2009) Genetic disruption of p38α Tyr323 phosphorylation prevents T-cell receptor-mediated p38α activation and impairs interferon-γ production. Blood 113, 2229–2237

32. Alam, M. S., Gaida, M. M., Ogawa, Y., Kolios, A. G., Lasitschka, F., and Ashwell, J. D. (2014) Counter-regulation of T cell effector function by differentially activated p38. J. Exp. Med. 211, 1257–1270

33. del Barco Barrantes, I., Coya, J. M., Maina, F., Arthur, J. S., and Nebreda, A. R. (2011) Genetic analysis of specific and redundant roles for p38α and p38β MAPKs during mouse development. Proc. Natl. Acad. Sci. U.S.A. 108, 12764–12769

34. Caballero-Franco, C., Choo, M. K., Sano, Y., Ritprajak, P., Sakurai, H., Otsu, K., Mizoguchi, A., and Park, J. M. (2013) Tuning of protein kinase circuitry by p38α is vital for epithelial tissue homeostasis. J. Biol. Chem. 288, 23788–23797

35. Hernández, G., Lal, H., Fidalgo, M., Guerrero, A., Zalvide, J., Force, T., and Pombo, C. M. (2011) A novel cardioprotective p38-MAPK/mTOR pathway. Exp. Cell Res. 317, 2983–2994

36. Wu, X. N., Wang, X. K., Wu, S. Q., Lu, J., Zheng, M., Wang, Y. H., Zhou, H., Zhang, H., and Han, J. (2011) Phosphorylation of Raptor by p38β participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation. J. Biol. Chem. 286, 31501–31511

37. Katholning, K., Kaltenecker, C. C., Hayakawa, H., Rosner, M., Lassnig, C., Zlabinger, G. J., Gaestel, M., Müller, M., Hengstschläger, M., Höfl, W. H., Park, J. M., Säemann, M. D., and Weichhart, T. (2013) p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin. J. Immunol. 190, 1519–1527

38. Li, Y., Inoki, K., Vacratsis, P., and Guan, K. L. (2003) The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14–3–3. J. Biol. Chem. 278, 13663–13671

39. Ronkina, N., Kotlyarov, A., Dittrich-Breiholz, O., Kracht, M., Hitti, E., Milarski, K., Askew, R., Marusic, S., Lin, L. L., Gaestel, M., and Telliez, J. B. (2007) The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell Biol. 27, 170–181

40. Zaru, R., Ronkina, N., Gaestel, M., Arthur, J. S., and Watts, C. (2007) The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat. Immunol. 8, 1227–1235

41. Sauer, S., Bruno, L., Hertweck, A., Finlay, D., Leleu, M., Spivakov, M., Knight, Z. A., Cobb, B. S., Cantrell, D., O’Connor, E., Shokat, K. M., Fisher, A. G., and Merkenschlager, M. (2008) T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. U.S.A. 105, 7779–7802

42. Delgoffe, G. M., Kole, T. P., Zheng, Y., Zarek, P. E., Matthews, K. L., Xiao, B., Worley, P. F., Kozma, S. C., and Powell, J. D. (2009) The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844

43. Gottschalk, R. A., Corse, E., and Allison, J. P. (2010) TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J. Exp. Med. 207, 1701–1711

44. Moran, A. E., Holzapfel, K. L., Xing, Y., Cunningham, N. R., Maltzman, J. S., Punt, J., and Hoqquist, K. A. (2011) T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208, 1279–1289

45. McGuire, V. A., Gray, A., Monk, C. E., Santos, S. G., Lee, K., Aubareda, A., Crowe, J., Ronkina, N., Schwermann, J., Batty, I. H., Leslie, N. R., Dean, J. L., O’Keefe, S. J., Boothby, M., Gaestel, M., and Arthur, J. S. (2013) Cross talk between the Akt and p38α pathways in macrophages downstream of Toll-like receptor signaling. Mol. Cell Biol. 33, 4152–4165

46. Gomez-Rodriguez, J., Wohlfert, E. A., Handon, R., Meylan, F., Wu, J. Z., Anderson, S. M., Kirby, M. R., Belkaid, Y., and Schwartzberg, P. L. (2014) Ikt-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J. Exp. Med. 211, 529–543

47. Atherly, L. O., Brehm, M. A., Welsh, R. M., and Berg, L. J. (2006) Tec kinases Itk and Blk are required for CD8⁺ T cell responses to virus infection independent of their role in CD4⁺ T cell help. J. Immunol. 176, 1571–1581

48. Beardmore, V. A., Hinton, H. J., Eftychi, C., Apostolaki, M., Armaka, M., Darragh, J., McBrath, J., Carr, J. M., Armit, L. J., Clacher, C., Malone, L., Kollias, G., and Arthur, J. S. (2005) Generation and characterization of p38β (MAPK11) gene-targeted mice. Mol. Cell Biol. 25, 10454–10464

49. Park, J. M., Ng, V. H., Maeda, S., Rest, R. F., and Karin, M. (2004) Anthracycin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J. Exp. Med. 200, 1647–1655